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Background: The study of muscle metabolism by near-infrared spectroscopy (NIRS) has been poorly implemented
in multiple sclerosis (MS). Aims of the study were to compare resting muscle oxygen consumption (rmVO2) at
gastrocnemius in MS patients and in age-matched healthy controls (HC) measured using NIRS, and to evaluate its
possible relationship with patients’ mobility.
Methods: Twenty-eight consecutively enrolled MS patients (male, n = 16; age = 42.7 ± 14.0 y, Relapsing-Remitting,
n = 19; Primary-Progressive, n = 9) and 22 HC (male, n = 13; age = 36.0 ± 8.2 y) were studied during rest applying the
NIRS probes at gastrocnemius, producing a venous occlusion at the thigh using a cuff, and analyzing the slope of
the total hemoglobin to calculate rmVO2. Mobility was assessed by a 6-Minute Walking Test and 6-Minute Walking
Distance (6MWD) was recorded.
Results: rmVO2 was higher in MS compared to HC (0.059 ± 0.038 vs 0.039 ± 0.016 mlO2/min/100 g, P < 0.003), not
different in clinical subtypes, not correlated to patients’ characteristics (age, disease duration, Expanded Disability
Status Scale, resting heart rate, skinfold thickness), and significantly higher in patients with lower walking ability
(6MWD < 450 m, n = 12) compared to those at better performance (respectively, 0.072 ± 0.043 vs 0.049 ± 0.032
mlO2/min/100 g, P = 0.03).
Conclusion: rmVO2 values, significantly higher in MS patients compared to HC, and in low versus high performing
patients, might represent a marker of peripheral adaptations occurred to sustain mobility, as observed in other
chronic diseases.
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Multiple Sclerosis (MS) is a neurological disorder char-
acterized by inflammatory demyelination and neuro-
degeneration within the central nervous system. This
condition leads to a variety of symptoms, among which
reduced mobility, weakness and fatigue are common and
key problems [1,2], apparently due to alterations in both
central motor drive and intramuscular function [2]. The
study of muscle metabolism in MS by Near-Infrared
Spectroscopy (NIRS) has been poorly implemented.
NIRS is a technique that allows the non-invasive study
of muscle metabolism in static and dynamic conditions* Correspondence: mlgnmr@unife.it
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reproduction in any medium, provided the orin health and disease [3-9]. A parameter that can be
easily measured by NIRS is the local resting muscle
oxygen consumption (rmVO2) [10], which allows a
quantification of the muscle’s capacity to extract oxygen
from blood. This parameter was found to be impaired
in legs of patients with chronic diseases [5,7,8,11,12],
and modified following exercise training in peripheral
arterial disease (PAD) [13]. Therefore, rmVO2 might be
potentially useful in a clinical setting for assessing the
level of skeletal muscle metabolic impairment, and for
detecting muscle modifications following the progression
of the disease, therapeutic treatments or rehabilitative
programs. We hypothesized that muscle adaptations might
also occur and be detectable in MS.
This cross-sectional study aims: i) to compare the
rmVO2 values at gastrocnemius collected on a sample ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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possible differences in MS clinical subtypes; and ii) to
evaluate possible relationships between rmVO2 values
and MS patients’ mobility.
Methods
Subjects
Twenty-eight MS patients referred from a regional MS
were consecutively enrolled (male, n = 16; age = 42.7 ±
14.0 y). Inclusion criteria: adult patients with MS clinic-
ally defined according to the McDonald criteria [14].
Exclusion criteria: Expanded Disability Status Scale score
(EDSS) > 6 [15], comorbidities affecting oxygen transport,
delivery and extraction (e.g. severe anemia, PAD, etc.),
acute relapse within the previous 30 days.
Twenty-two healthy age-matched adults were randomly
recruited among rehabilitation laboratory staff (male,
n = 13; age = 36.0 ± 8.2 y). All participants gave written
informed consent. The study was approved by the ethics
committee of Ferrara, Italy.
Resting muscle oxygen consumption by Near-Infrared
Spectroscopy
NIRS measurements were obtained with a continuous
wave system (Oxymon-MK III, Artinis Medical Systems,
Netherlands) providing measures of changes in oxy-
and deoxyhemoglobin concentrations. This system, which
consists of 2 channels (2 equivalent pulsed light sources,
2 avalanche photodiode detectors, shielding from ambient
light), uses intensity-modulated light at a frequency of 1
MHz and laser diodes at 3 wavelengths (905, 850, and
770 nm) corresponding to the absorption wavelengths
of oxy- and deoxyhemoglobin, with an autosensing
power supply (approximately 40 W at 110–240 V). The
light from the laser diodes is conducted from the in-
strument to the tissue and back along 3m-long optical
glass fibers.
After measuring adipose tissue thickness (ATT) accor-
ding to international standards [16] along the medial
aspect of gastrocnemius muscle, NIRS sensors were
placed at the same level. The interoptode distance was
maintained at 4 cm, allowing a maximum penetration
depth of light around 20 mm. As previously reported
[12], rmVO2 was measured with the subject resting in a
supine position by rapidly inflating a cuff placed around
the thigh to a pressure of 60 mmHg to obtain venous
occlusion. The pneumatic cuff was quickly released
after 30 seconds. The absolute rmVO2 value was calcu-
lated by the rate of increase in concentrations once the
venous outflow had been blocked [17]. Data collection
and calculation were performed using the software
Oxysoft 47 (Artinis Medical Systems, Netherlands).
During NIRS evaluation, resting heart rate (rHR) was
recorded by a heart rate monitor (Sport Tester-RS400,Polar Electro-Oy, Kempele, Finland) and the mean value
was considered for the analysis. Measurements were
obtained by the same operators.
Mobility assessment
MS patients were asked to perform a 6-min walking
test (6MWT), considered as a feasible, reproducible,
and reliable measure providing sensitive information
about the walking performance of persons with MS
[18,19]. Patients were instructed to walk up and down a
22 m corridor at their own pace for 6 minutes, aiming
to cover as much distance as possible. The distance
completed after 6 minutes (6MWD) was recorded.
Statistical analysis
Data are expressed as means ± standard deviations. The
normal distribution of the data was verified by the
Kolmogorov-Smirnov test. Comparison of demographics
was performed using unpaired Student T-tests and
Fisher’s exact test, as appropriate. Differences between
subgroups were measured by an unpaired Student T-test
or One-way ANOVA test, as appropriate. A Pearson
correlation was performed to evaluate the relationship
between rmVO2 values in MS patients and possible influ-
encing variables (age, disease duration, rHR, ATT). A
Pearson correlation was also performed to evaluate a
possible relationship between rmVO2, and EDSS, Pyramidal
Functions (PF) subscale score of Kurtzke Functional
Systems Scores [15], 6MWD, and rHR.
Analysis was performed considering rmVO2 values of
both legs, and the mean value of the two legs of each
subject, when appropriate.
Significance was set at a P-value ≤ 0.05. Statistics were




Among the MS population, 19 patients were a Relapsing
Remitting (RR) clinical type, and 9 were Primary Pro-
gressive (PP). PP patients were older than HC and RR
(P < 0.001). Characteristics of study participants are
presented in Table 1.
Resting muscle oxygen consumption values in MS
patients and healthy controls
ATT and rmVO2 were safely measured in both legs for
all MS (n = 56) and HC (n = 44). ATT was less than 20
mm for all participants.
rmVO2 values of both legs resulted in being signifi-
cantly higher in all MS compared to healthy (P = 0.003),
even separately RR and PP (P = 0.009) (Table 2, Figure 1).
PP showed the highest rmVO2 values, but no significant
difference with respect to RR and HC.

















Age (years) 42.7 ± 14.0 34.2 ± 7.6 60.3 ± 4.3† 36.0 ± 8.2
Disease
duration (years)
9.9 ± 6.3 7.4 ± 3.3 14.4 ± 8.5 –
EDSS 2.7 ± 1.6 1.9 ± 1.0 4.3 ± 1.3 –
MS, Multiple Sclerosis; RR, Relapsing Remitting; PP, Primary Progressive; HC,
healthy controls; EDSS, Expanded Disability Status Scale.
Figure 1 Comparison between rmVO2 values of legs of healthy
and MS subjects. Legend to figure: rmVO2, resting muscle oxygen
consumption; HC, healthy controls, MS, Multiple Sclerosis; RR, Relapsing
Remitting; PP, Primary Progressive. Statistical analysis: Unpaired Student
T-test between HC and all MS; One-way ANOVA among HC, RR, and PP.
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two legs for each subject) were observed in patients with
EDSS ≤ 2 (n = 14) compared to patients with EDSS >2
(n = 14) (respectively 0.051 ± 0.029 vs 0.067 ± 0.040
mlO2/min/100 g, P = n.s.). A similar pattern was depicted
comparing rmVO2 values of patients categorized in
two groups according to the PF subscale score, more
strictly related to muscular functions (PF ≤ 1, n = 16 vs
PF > 1, n = 12, respectively 0.051 ± 0.027 vs 0.069 ±
0.043 mlO2/min/100 g, P = n.s.).
rHR was significantly higher in all MS patients com-
pared to HC (P = 0.02) (Table 2).
No significant relationship was found in all MS pa-
tients, and in clinical types separately, between EDSS
and rmVO2 values (mean of the two legs for each subject),
as well as considering the PF subscale score (mean
value = 1.8 ± 1.1).
No significant relationships were found between the
rmVO2 values of all MS patients, considering possible
influencing factors (age, disease duration, rHR, ATT),
even evaluating clinical types separately. In all MS a
trend towards a direct relationship between rHR and
rmVO2 (mean of the two legs for each subject) (r = 0.37,
P = 0.065) was observed.
Resting muscle oxygen consumption and mobility
All MS patients performed the 6MWT. The mean value





















rHR (beats/min) 85 ± 10* 83 ± 11 89 ± 8 79 ± 6
MS, Multiple Sclerosis; RR, Relapsing Remitting; PP, Primary Progressive; HC,
healthy controls; rmVO2, resting muscle oxygen consumption; rHR, resting
heart rate.
*P < 0.05 by Unpaired Student T-test between all MS and HC;
† P < 0.05 by One way-ANOVA among RR, PP, and HC.On the basis of the mean walking speed of healthy
individuals of the same age (1.26 m/sec) [20], patients
were categorized in two groups, a group of lower walking
ability (n = 12, PP, n = 9, RR, n = 3) and a group of better
performance (n = 16, RR, n = 16, PP, n = 0), considering
a cut-off in 6MWD equal to 450 m.
The group of lower walking ability showed significantly
higher rmVO2 values of both legs compared to the group
of better performance (P = 0.03) (Table 3), and healthy
controls (P < 0.001) (Figure 2). As additional observation,
the same significant difference was highlighted consid-
ering the rHR (P < 0.004) (Table 3). Furthermore, in the
entire MS population, 6MWD was also found inversely
correlated to rHR (r = −0.44, P = 0.02), whilst no correl-
ation was found with rmVO2 values (mean of the two
legs for each subject).
Discussion
The present study, to the best of our knowledge, for the
first time deals with the measurement of rmVO2 byTable 3 Comparison between the two subgroups of MS









Legs (n) 24 32
6MWD (m) 294.3 ± 106.8 636.6 ± 70.5 <0.0001
rmVO2 (mlO2/
min/100g)
0.072 ± 0.043 0.049 ± 0.032 =0.03
rHR
(beats/min)
91 ± 9 81 ± 9 <0.004
MS, Multiple Sclerosis; 6MWD, 6 Minute Walking Distance; rmVO2, resting
muscle oxygen consumption; rHR, resting heart rate.
Figure 2 Comparison between rmVO2 values of legs of MS
population ranked according to mobility. Values of healthy
controls were also included. Legend to figure: rmVO2, resting muscle
oxygen consumption; MS, Multiple Sclerosis; HC, healthy controls.
Statistical analysis: Unpaired Student T-test between MS low and high
mobility; One-way ANOVA among MS low and high mobility, and HC.
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venous occlusion was found to be significantly higher in
MS patients than in healthy subjects, in absence of
differences between clinical subtypes, EDSS and PF
subscale scores, and with no correlation to patients’ age,
disease duration, rHR, ATT, EDSS, and PF subscale
score. Interestingly, low performing patients showed
higher rmVO2 values compared to better performing
subjects, as well as a higher resting heart rate.
The rmVO2 parameter was also studied in some other
patients with chronic diseases, such as chronic heart
failure (CHF) [11] and PAD [12]. Lower rmVO2 values
at brachioradialis muscle have been observed in pa-
tients with CHF compared to healthy subjects [11]. Just
in another population with walking impairment as PAD
patients, compared to healthy subjects, did we observe
rmVO2 values at gastrocnemius by venous occlusion,
which were significantly higher in more severely diseased
patients [12], similar to those observed in the present
MS population. In that case a possible compensatory
mechanism to the lack of oxygen has been hypothe-
sized. To support this hypothesis of plastic peripheral
adaptations in the O2 system, different rmVO2 values
were observed in the legs of PAD patients after a 6-
month exercise program, with increased values in limbs
without hemodynamic improvements and lower changes
(decrease) in the limbs less ischemic following rehabili-
tation [13].
In MS patients where blood flow restrictions are not
present, an abnormal pattern of muscle fiber compos-
ition and size with respect to healthy people has been
observed, with fewer type I fibers, a shift towards whitefibers, and smaller fibers of all types [2]. This picture
seems to be consistent with the pattern described in
subjects exposed to deconditioning [2]. In a group of
chronic stroke survivors, values of rmVO2 superimpos-
able to those observed in MS patients were observed in
the hemiplegic leg, with a decrease to reach the lower
values of the unaffected limb after 10 weeks of over-
ground gait training (unpublished data).
Therefore, it seems that a pathological (neurologic or
vascular) condition plus a deconditioning phase is re-
sponsible for an adaptive increase of this parameter.
However, skeletal muscle energetic status during rest
does not seem significantly impaired in MS compared
to healthy subjects, with no indication of metabolic in-
flexibility or mitochondrial dysfunction [21], thus with
a likely normal adaptive attitude. Our results in MS
patients might be explained assuming that the residual
type I fibers develop a greater metabolic activity and
enhanced capillarization as a compensatory mechanism to
sustain walking endurance capacity and fatigue. Other-
wise, variation in artero-venous difference is a factor
influencing rmVO2 together with the blood flow, per
se, potentially supported by the higher rHR observed in
MS patients, and more in lower performing ones, com-
pared to HC.
This preliminary study, with its limitations due to the
small sample size and NIRS technique (limited region
of muscle evaluated, variability of probe position, ATT,
etc.), sheds some light on non-invasive muscle evaluation
by NIRS in MS. rmVO2 at gastrocnemius, a quick and
painless measurement suitable for a clinical setting [12],
might represent a biomarker of peripheral adaptations
related to patients’ mobility. It was found to be stable
in repeated measurements in normally active, healthy
subjects, and modified following 6-month training in PAD
patients with a different adaptive response according to
the hemodynamic changes observed in each leg [13].
Along these lines, investigations into rmVO2 might be an
interesting issue in MS, for the purpose of monitoring
rehabilitative programs. In the present study, we focused
on gastrocnemius, based on previous experience [12,13],
and its relation to mobility. However, other muscle groups
can also be measured to observe whether changes in
rmVO2 occur in MS during the progression of the disease
or in response to treatments.
Conclusions
rmVO2 values measured by NIRS were found to be
significantly higher in MS patients compared to HC, and
in low versus better performing patients. Such parameter
might represent a marker of peripheral adaptations oc-
curred to sustain mobility. It might be potentially useful
in a clinical setting for assessing the level of skeletal
muscle metabolic impairment, and for monitoring the
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rehabilitative programs.
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